Table 2. Cox regression analysis of patient features, NHS Trust trial entry and the patient's receipt of chemotherapy on overall survival.
| Total patients (N=7782) | Deaths (N=6981) | %a | Unadjusted HR | Adjusted HRb | P-value c | |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 4206 | 3838 | 91 | <0.001 | ||
| Female | 3576 | 3143 | 88 | 0.84 (0.80, 0.88) | 0.86 (0.82, 0.90) | |
| Age quintile (years) | ||||||
| 1 (30–62) | 2161 | 1859 | 86 | <0.001 | ||
| 2 (63–69) | 1917 | 1731 | 90 | 1.22 (1.14, 1.30) | 1.12 (1.04, 1.21) | |
| 3 (70–75) | 1757 | 1561 | 89 | 1.31 (1.23, 1.40) | 1.20 (1.11, 1.30) | |
| 4 (76–80) | 1159 | 1079 | 93 | 1.62 (1.51, 1.75) | 1.31 (1.19, 1.44) | |
| 5 (81–101) | 788 | 751 | 95 | 2.07 (1.90, 2.25) | 1.47 (1.32, 1.64) | |
| Performance status | ||||||
| PS 0 | 975 | 772 | 79 | <0.001 | ||
| PS 1 | 1919 | 1653 | 86 | 1.39 (1.28, 1.52) | 1.34 (1.24, 1.45) | |
| PS 2 | 1437 | 1344 | 94 | 2.19 (2.01, 2.40) | 1.83 (1.67, 2.00) | |
| PS 3 | 868 | 847 | 98 | 3.82 (3.46, 4.21) | 2.65 (2.36, 2.99) | |
| PS 4 | 269 | 265 | 99 | 8.63 (7.40, 9.95) | 5.01 (4.05, 6.19) | |
| Missing | 2314 | 2100 | 91 | 1.86 (1.71, 2.02) | 1.63 (1.50, 1.77) | |
| Stage | ||||||
| Limited | 1319 | 1043 | 79 | 0.001 | ||
| Extensive | 3053 | 2894 | 95 | 2.45 (2.28, 2.63) | 2.07 (1.92, 2.25) | |
| Missing | 3410 | 3044 | 89 | 1.74 (1.62, 1.87) | 1.43 (1.31, 1.57) | |
| Townsend quintile | ||||||
| 1 (Most affluent) | 1075 | 947 | 88 | 0.341 | ||
| 2 | 1378 | 1234 | 90 | 1.04 (0.96, 1.13) | 1.07 (0.98, 1.17) | |
| 3 | 1523 | 1365 | 90 | 1.08 (0.99, 1.17) | 1.07 (0.97, 1.17) | |
| 4 | 1650 | 1490 | 90 | 1.05 (0.97, 1.14) | 1.07 (0.98, 1.18) | |
| 5 (Least affluent) | 2138 | 1929 | 90 | 1.05 (0.97, 1.13) | 1.07 (0.96, 1.19) | |
| Missing | 18 | 16 | 89 | 1.13 (0.69, 1.85) | 1.52 (1.15, 2.02) | |
| Ethnic group | ||||||
| White | 6015 | 5439 | 90 | 0.422 | ||
| Black | 31 | 26 | 84 | 0.71 (0.49, 1.05) | 0.79 (0.56, 1.11) | |
| Asian | 396 | 344 | 87 | 1.06 (0.95, 1.19) | 1.01 (0.88, 1.15) | |
| Mixed | 14 | 11 | 79 | 0.69 (0.38, 1.24) | 0.78 (0.47, 1.31) | |
| Other | 37 | 32 | 87 | 1.00 (0.71, 1.42) | 0.84 (0.46, 1.52) | |
| Missing | 1289 | 1129 | 88 | 1.00 (0.93, 1.06) | 1.04 (0.94, 1.14) | |
| Charlson index | ||||||
| 0 | 3466 | 3015 | 87 | <0.001 | ||
| 1 | 1483 | 1301 | 88 | 1.23 (1.15, 1.32) | 1.07 (1.01, 1.14) | |
| 2 or 3 | 1080 | 967 | 90 | 1.35 (1.25, 1.45) | 1.11 (1.02, 1.22) | |
| 4+ | 1753 | 1698 | 97 | 2.09 (1.97, 2.22) | 1.62 (1.49, 1.77) | |
| Chemotherapy | ||||||
| No | 2967 | 2825 | 95 | <0.001 | ||
| Yes | 4815 | 4156 | 86 | 0.43 (0.41, 0.45) | 0.51 (0.46, 0.56) | |
| Trial entry (%) | ||||||
| <5 | 5282 | 4739 | 90 | 0.83 | ||
| >5 | 2500 | 2242 | 90 | 0.96 (0.91, 1.01) | 0.99 (0.88, 1.10) | |
Abbreviations: HR=hazard ratio; NHS=National Health Service.
Percentage of patients from each subgroup who have died.
HR adjusted for all other variables in the table. Analysis clustered by the NHS Trust features.
All non-binary variables are tested for trend except ethnicity, which is a likelihood ratio test.
All missing values were removed prior to the calculation of probability.
A total of 63 patients had a date of diagnosis on or before their date of death, and were excluded from survival analyses (N=7782).